Tariffs hit small pharma and AI startups
Reporting says new U.S. tariffs will disproportionately affect smaller and mid‑sized pharmaceutical exporters that rely on the U.S. market, while wider trade friction is also reshaping the economics of AI startups. Analysts argue the effects show up in higher costs, slower hiring and pressure on enterprise adoption as hardware and supply‑chain economics tighten. (irishexaminer.com, startupfortune.com)
New United States tariffs on patented drug imports are landing hardest on smaller exporters that depend on the American market, while the same trade squeeze is pushing up costs for artificial intelligence startups. (whitehouse.gov, whitehouse.gov, startupfortune.com) The White House said last week the tariffs were imposed under Section 232 after a national-security review found the United States makes only 15% of patented active pharmaceutical ingredients by volume for its own market. The administration said the policy is meant to pull more drug manufacturing onshore. (whitehouse.gov, whitehouse.gov) For Irish exporters, the exposure is unusually high. Ireland’s Central Statistics Office said chemicals and related products, including medical and pharmaceutical goods, made up 91% of Irish exports to the United States in February 2025, and exports to the United States reached €12.9 billion that month. (cso.ie) Irish business groups had warned before the new drug tariffs that smaller firms would have less room to absorb a hit to margins or reroute supply chains. Ibec said United States-bound goods account for more than 24% of Ireland’s national income and that pharmaceuticals had been exempt from earlier tariff rounds but could still be targeted later. (ibec.ie, enterprise.gov.ie) Artificial intelligence startups face the same problem in a different form: they buy computing power the way factories buy steel. Startup Fortune reported that tariff-driven increases in chip and server costs are raising training and deployment bills for smaller companies that cannot negotiate the prices available to Microsoft, Amazon or Google. (startupfortune.com) That pressure arrives as large companies are already scrutinizing returns from artificial intelligence spending. Nvidia said in its 2026 State of AI report that businesses are focusing more tightly on return on investment and practical use cases, a tougher backdrop for startups selling expensive tools into cautious enterprise budgets. (nvidia.com) The tariff policy is also uneven by country. The United States Trade Representative said in December 2025 that United Kingdom-origin pharmaceuticals and ingredients would be exempt from Section 232 tariffs under a bilateral deal, leaving exporters without similar carve-outs at a disadvantage. (ustr.gov, ustr.gov) The White House says the tariffs have already prompted about $400 billion in new pharmaceutical investment commitments in the United States. For smaller drug exporters and artificial intelligence startups, the nearer-term math is simpler: higher input costs, tighter hiring plans and less room for error. (whitehouse.gov, startupfortune.com)
